Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP701 (Apurano Pharmaceuticals GmbH)
- Development stage
- Unknown
- Lead developer
- Apurano Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oromucosal
01
Overview
AP701 is an oromucosal cannabinoid spray developed by Apurano Pharmaceuticals and marketed by CannaXan GmbH. It utilizes a lipid-based nanoparticular drug formulation standardized to Δ-9-tetrahydrocannabinol (THC), which is designed to enhance the bioavailability of the active cannabinoid. THC acts as an agonist at the cannabinoid receptors CB1 and CB2, modulating pain signaling and neurological symptoms. AP701 is chemically identical to the compound drug formulation CannaXan 701-1.1, which is available in Germany and Austria. The drug has been investigated in Phase I clinical trials for its pharmacokinetics and tolerability, with potential therapeutic applications in chronic pain and multiple sclerosis.
- Brand names
- CannaXan 701-1.1CannaXan701-1.1CannaXan-701-1.1
- Other names
- CannaXan 701CannaXan701CannaXan-701delta-9-tetrahydrocannabinol nanoparticle formulationdelta9-tetrahydrocannabinol nanoparticle formulationdelta 9-tetrahydrocannabinol nanoparticle formulation
02
Targets
CNR1 (Cannabinoid receptor 1)Δ9-THC (Delta-9-tetrahydrocannabinol)
Beyond the preview
Go deeper on AP701 (Apurano Pharmaceuticals GmbH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP701 (Apurano Pharmaceuticals GmbH).